Newborn

First years of experience on LSD screening in Italy, Padova

April 22, 2021

First years of experience on LSD screening in Italy, Padova

Giulia Polo is lab supervisor at the Regional Center for Expanded Neonatal Screening, University Hospital of Padova, Italy discusses her experiences with screening for lysosomal storage diseases (LSDs) in newborns.

Activities of acid β-glucocerebrosidase (ABG; Gaucher), acid α-glucosidase (GAA; Pompe), acid α-galactosidase (GLA; Fabry), and acid α-Liduronidase (IDUA; MPS-I) in dried blood spots (DBS) from all newborns during a 31-month period were determined by multiplexed tandem mass spectrometry (MS/MS) using the NeoLSD® assay system.

From September 2015 to April 2018, 85,445 newborns were screened for the four LSDs. We recalled 96 neonates (0.11%) for collection of a second DBS. Low activity was confirmed in 43, who had confirmatory testing. 16/43 had pathogenic mutations: four Pompe, four Gaucher, six Fabry, and two MPS-I. The incidences of Pompe and Gaucher diseases were similar (1/21,361), with Fabry disease the most frequent (1/ 14,241) and MPS-I the rarest (1/ 42,723). The combined incidence of the four disorders was 1:6,572 births. Simultaneously determining multiple enzyme activities by MS/MS, with a focus on specific biochemical markers, successfully detected newborns with LSDs. The high incidence of these disorders supports this screening program.
GET IN TOUCH

Take the next step

GET IN TOUCH

Speak with a sales person

Talk to one of our product experts about the right solutions for you.

Contact us today

View more resources

Explore our articles and resources section for the latest information

Learn More

Read the lastest news

Sign up for our newsletter to find out about the latest news from PerkinElmer and the industry

Sign up

The presentations are available for educational exchange purposes only. Products mentioned in the presentations may not be available in your country. Please consult your local PerkinElmer representative to check the products availability in your country.